Revealing the mechanism of how cardiac myosin-binding protein C N-terminal fragments sensitize thin filaments for myosin binding

Alessio V. Inchegolo\textsuperscript{a}, Samantha Beck Previs\textsuperscript{b,c}, Michael J. Previs\textsuperscript{b,c}, David M. Warshaw\textsuperscript{b,c,1}, and Neil M. Kad\textsuperscript{a,1}

\textsuperscript{a}School of Biosciences, University of Kent, Canterbury CT2 7NH, United Kingdom; \textsuperscript{b}Department of Molecular Physiology and Biophysics, University of Vermont, Burlington, VT 05405; and \textsuperscript{c}Cardiovascular Research Institute, University of Vermont, Burlington, VT 05405

Edited by James A. Spudich, Stanford University School of Medicine, Stanford, CA, and approved February 20, 2019 (received for review September 27, 2018)

Cardiac muscle contraction is triggered by calcium binding to troponin. The consequent movement of tropomyosin permits myosin binding to actin, generating force. Cardiac myosin-binding protein C (cMyBP-C) plays a modulatory role in this activation process. One potential mechanism for the N-terminal domains of cMyBP-C to achieve this is by binding directly to the actin-thin filament at low calcium levels to enhance the movement of tropomyosin. To determine the molecular mechanisms by which cMyBP-C enhances myosin recruitment to the actin-thin filament, we directly visualized fluorescently labeled cMyBP-C N-terminal fragments and GFP-labeled myosin molecules in thin filaments in a fluorescence-based single-molecule microscopy assay. Binding of the C0C3 N-terminal cMyBP-C fragment to the thin filament enhanced myosin association at low calcium levels. However, at high calcium levels, C0C3 bound in clusters, blocking myosin binding. Dynamic imaging of thin filament-bound Cy3-C0C3 molecules demonstrated that these fragments diffuse along the thin filament before statically binding, suggesting a mechanism that involves a weak-binding mode to search for access to the thin filament and a tight-binding mode to stabilize the thin filament to calcium, thus enhancing myosin binding. Although shorter N-terminal fragments (Cy3-C0C1 and Cy3-C0C1f) bound to the thin filaments and displayed modes of motion on the thin filament similar to that of the Cy3-C0C3 fragment, the shorter fragments were unable to sensitize the thin filament. Therefore, the longer N-terminal fragment (C0C3) must possess the requisite domains needed to bind specifically to the thin filament in order for the CMyBP-C N terminus to modulate cardiac contractility.

Cardiac myosin-binding protein C (cMyBP-C) modulates cardiac contraction at the level of the sarcomere. Mutations in the cMyBP-C gene are a major cause of hypertrophic cardiomyopathy (1), a disease that affects up to 1 in 200 people (2) and is the leading cause of sudden cardiac death in young adults (1, 3). cMyBP-C is composed of 11 subdomains from C0 to C10 (Fig. L4), 8 Ig-like and 3 Fn(III)-like with a proline–alanine-rich region between C0 and C1, and a linker between C1 and C2 (i.e., M-domain) (4). Each cMyBP-C molecule is tethered through its C terminus (5) to the myosin thick filament (6), while its N-terminal domains are free to contact either the myosin head region or the actin thin filament (7) (Fig. L4). Specifically, cMyBP-C interactions with myosin have been shown to occur through the S2 region (8–11), the myosin regulatory light chain (RLC) (12) and the S1 head (13), which may serve to stabilize myosin’s superrelaxed state (14–16) through interactions with the recently defined myosin mesa region (13, 17). In addition to myosin binding, cMyBP-C interacts with actin via its N-terminal domains (C0–C2) (18–21). These binding-partner interactions are believed to functionally impact cardiac contractility. For example, cMyBP-C knockout mouse cardiomyocytes (22) demonstrate a decrease in calcium sensitivity while N-terminal fragments infused into skinned fibers result in an increase in calcium sensitivity. Accordingly, fluorescence assays in muscle cells (10) have demonstrated that cMyBP-C N-terminal fragments activate muscle at low calcium levels and inhibit maximal activity at high calcium, suggesting dual roles in modulating contraction in vivo.

Mechanistically, muscle activation occurs by calcium-dependent shifts in the position of tropomyosin on the thin filament (22, 23). Tropomyosin binds axially along the thin filament (Fig. L4) and shifts azimuthally when calcium binds to the tropomyosin-associated tropodomin protein complex. Three positions of tropomyosin have been structurally (24) and functionally (25) defined: blocked (stERICALLY preventing myosin binding), closed (myosin can bind weakly), and open (myosin binding is unperturbed). It has been proposed that the cMyBP-C N terminus could sensitize the thin filament to calcium through the displacement of tropomyosin from its blocked to its closed position, to enhance myosin binding (21). The function of the cMyBP-C N-terminal subdomains COC3, COC1, and COC1f (i.e., COC1 including the first 17 M-domain residues) have been extensively characterized for their ability to sensitize the thin filament to calcium using in vitro motility (18, 26, 27), ATPase assays (19), and electron micrographic studies (21, 28). Our previous studies and that of others show that all three bind to actin, but only the COC3 fragment can both activate contractility.

Significance

Diverse demands on cardiac muscle require the fine-tuning of contraction. Cardiac myosin binding protein-C (cMyBP-C) is involved in this regulation; however, its precise molecular mechanism of action remains uncertain. By imaging the interactions of single myosin and cMyBP-C molecules interacting with suspended thin filaments in vitro we observe cMyBP-C N-terminal fragments assist activation and modulate contraction velocity by affecting myosin binding to the thin filament. Fluorescent imaging of Cy3-labeled cMyBP-C revealed that it diffusively scans the thin filament and then strongly binds to displace tropomyosin and activate at low calcium. At high calcium, cMyBP-C decorates the filament more extensively, reducing myosin binding through competition with binding sites. Understanding the mechanism of MyBP-C action has important implications for heart disease.

Author contributions: A.V.I., M.J.P., D.M.W., and N.M.K. designed research; A.V.I., S.B.P., and M.J.P. performed research; A.V.I., M.J.P., D.M.W., and N.M.K. analyzed data; and A.V.I., M.J.P., D.M.W., and N.M.K. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).

1To whom correspondence may be addressed. Email: david.warshaw@uvm.edu or N.Kad@kent.ac.uk.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1816480116/-/DCSupplemental.

Published online March 15, 2019.
thin filament sliding at low (0.1 μM) calcium and inhibit sliding at high (100 μM) calcium levels. In contrast, the shortest fragment, the murine C0C1f, does neither, while the C0C1f with its additional 17 residues of the M-domain can only inhibit thin filament sliding at high calcium (18). These differential functions may allow assignment of specific functional capacities to cMyBP-C’s N-terminal domains.

To define the molecular basis of thin-filament activation by cMyBP-C, we used a single-molecule suspended thin filament assay (Fig. 1B), in which we could directly observe the calcium-dependent binding of individual fluorescently labeled myosin-S1 molecules to the thin filament (29). Using all three murine cMyBP-C N-terminal fragments (Fig. 2B), C0C3, C0C1, and C0C1f, we show that cMyBP-C’s N terminus (C0C3) can maximally activate the thin filament, permitting myosin-S1 to bind even at low calcium. However, at high calcium with the thin filament maximally activated cMyBP-C can decrease myosin-S1 binding. By imaging fluorescently labeled cMyBP-C N-terminal fragments we observed these molecules individually binding directly to the thin filament. Once bound, the cMyBP-C fragments both diffuse along the thin filament and bind statically, with enhanced static binding observed only for the C0C3 fragment at high calcium levels that maximally activate the thin filament. These fragment binding and motion behaviors on the thin filament provide direct mechanistic insight into how cMyBP-C achieves both calcium sensitization at low calcium and thus modulation of cardiac contractility.

Results

The Effect of cMyBP-C N-Terminal Domains on S1-GFP Myosin Binding to the Thin Filament. We studied how each of the three N-terminal fragments C0C3, C0C1f, and C0C1 (Fig. 2) affects myosin binding to thin filaments (18–21), by directly measuring individual S1-GFP molecules interacting with thin filaments in their presence. Using 1 μM unlabeled cMyBP-C N-terminal fragments, we determined the level of S1-GFP (15 nM) binding to the thin filament at low and high calcium (0.1 μM and 100 μM, respectively). The fragment concentration was chosen based on past motility studies in which 1 μM C0C3 both sensitized the thin filament to calcium and inhibited thin filament motility at maximally activating calcium concentrations (30). Fig. 2A shows representative kymographs for interactions between 15 nM S1-GFP and a thin-filament tightrope at high calcium (pCa 4) and 0.1 μM ATP. Each x-axis pixel corresponds to a frame (300 ms), and each pixel on the y-axis corresponds to 126.4 nm along the tightrope.

Fig. 1. Thin filaments in vivo and in the single-molecule tightrope assay. (A) The subdomain structure of cMyBP-C and its spatial relationship to the thin filament (actin decorated with tropomyosin and the troponin complex TnT, TnI, and TnC) and myosin-containing thick filament in the sarcomere. (B) The thin-filament tightrope assay. Regulated thin filaments are suspended between surface-adhered beads using a microfluidic device and visualized using a high-N.A. objective lens. (C) A regulated thin filament labeled with AF633-phalloidin can be visualized suspended between two beads. (D) Representative kymograph of interactions between 15 nM S1-GFP and a thin-filament tightrope at high calcium (pCa 4) and 0.1 μM ATP. Each x-axis pixel corresponds to a frame (300 ms), and each pixel on the y-axis corresponds to 126.4 nm along the tightrope.
C0C1f or C0C1, at both low and high calcium. These results suggest that the shorter fragments are missing critical domains essential for modulating S1-GFP binding to the thin filament in a calcium-dependent manner.

**Imaging N-Terminal cMyBP-C Fragments Binding to the Thin Filament.**

As described above, only the C0C3 fragment affected S1-GFP binding to the thin filament in a calcium-dependent manner. Could the differential effects seen for the C0C3 fragment compared with the shorter C0C1f and C0C1 fragments be related to a difference in their binding to the thin filament? Therefore, we imaged 20 nM Cy3-tagged C0C3, C0C1f, and C0C1 interacting with thin filaments at both low and high calcium. Fig. 3 shows clear binding of all three fragments to the thin filaments using long-exposure (1 s) still images. These images were analyzed to determine the average number of fragment molecules bound per micrometer of thin filament. To ensure a more accurate determination of closely spaced, neighboring Cy3-C0C3 molecules, we fitted the distribution of intensities at low calcium to multiple Gaussians (29, 31) as detailed in SI Appendix, Fig. S1. Using the fluorescence intensity of a single Cy3, we converted each fluorescent spot intensity along a kymograph of S1-GFP binding in the absence and presence of C0C3, at low and high calcium, collected at 3.3 fps. (Fig. 2A) Representative kymographs of S1-GFP binding to regulated thin filaments. (A) For Cy3-C0C3 (Fig. 3A and D), there was a significant greater than fivefold increase in binding at high vs. low calcium [6.27 ± 1.15 molecules per μm (SEM, n = 2) vs. 0.84 ± 0.17 molecules per μm (SEM, n = 11)], respectively. This was not the case for Cy3-C0C1f (Fig. 3 B and D), where no significant (P = 0.55) change in decoration of thin filaments (in molecules per μm) was observed between low and high calcium [1.17 ± 0.21 (SEM, n = 9) vs. 1.56 ± 0.77 (SEM, n = 5) molecules per μm, respectively]. However, significantly more Cy3-C0C1 (Fig. 3 C and D)
bound to thin filaments at low \(2.57 \pm 0.45\) (SEM, \(n = 7\)) molecules per \(\mu m\) vs. high calcium \(0.85 \pm 0.51\) (SEM, \(n = 4\)) molecules per \(\mu m\). In summary, only C0C3 binding to the thin filament was substantially affected by calcium, resulting in increased binding at high calcium.

At high calcium, the binding of Cy3-C0C3 did not occur uniformly across thin filaments; instead, binding occurred in clusters (Fig. 3 and SI Appendix, Fig. S2), suggesting the possible existence of coordinated binding. To quantify this, we determined the number of molecules per fluorescent spot for Cy3-C0C3, the only fragment that showed increased binding at high calcium. Fig. 4 shows the distribution of number of molecules within each fluorescent spot or cluster on a thin filament for Cy3-C0C3 at low and high calcium. At low calcium, the majority of fluorescent spots contain only a single Cy3-C0C3; however, at high calcium the distribution is quite broad with its peak at four Cy3-C0C3 molecules per spot. To investigate the nature of these distributions we first tried fitting the high-calcium data to a Poisson distribution. The fit as shown in Fig. 4 (dotted line) does not adequately describe the data; however, the Poisson distribution has a peak value of 5.2, which suggests that Cy3-C0C3 is binding in clusters. For a more meaningful fit of Cy3-C0C3 binding, we used the mechanistic explanation of myosin binding to a calcium-regulated thin filament, which is based upon the accessibility of actin binding sites afforded by motions of tropomyosin across the thin filament (25). We propose that tropomyosin movements from the blocked to the closed state that occur either transiently or through calcium induction result in the exposure of cMyBP-C binding sites. Thus, upon Cy3-C0C3 binding, Cy3-C0C3 could stabilize the closed state, and because of the inherent stiffness of tropomyosin (32) this would expose more cMyBP-C binding sites locally on the thin filament. This mechanism is analogous to that of thin-filament activation by rigor myosin binding (33, 34). Therefore, here we utilized the model we described previously to explain the calcium-dependent activation of the thin filament (29) to fit Cy3-C0C3 binding data in Fig. 4. In brief, the model of Cy3-C0C3 binding to the thin filament (i.e., actin), which can adopt different states of activation, can be summarized by the following chemical equilibrium:

\[
A_B + Ca^{2+} \underset{K_B}{\overset{K_{Ca}}{\rightleftharpoons}} A_{Cl} + M \underset{K_{Cl}}{\overset{K_M}{\rightarrow}} A_{Cl,M}.
\]

\(A_B\) is in the blocked state, \(A_{Cl}\) is in the closed state and able to bind cMyBP-C (\(M\)), and \(A_{Cl,M}\) is in the closed state able to bind to \(d\) molecules of \(M\). The probability of \(M\) being attached to the thin filament (\(prob_{att}\)) is given by the ratio of time spent attached (\(\tau_{on}\)) vs. the sum of \(\tau_{on}\) and the time spent detached (\(\tau_{off}\)):

\[
prob_{att} = \frac{\tau_{on}}{\tau_{on} + \tau_{off}}.
\]

where \(\tau_{on}\) is a measured parameter (SI Appendix, Fig. S3). \(\tau_{off}\) depends on the proportion of thin filaments in the \(A_{Cl,M}\) state.

Fig. 3. Fluorescent cMyBP-C N-terminal fragments associate with thin filament tightropes. Representative images of tightropes decorated using 20 nM Cy3-tagged (A) C0C3, (B) C0C1f, and (C) C0C1, in low and high calcium conditions. (D) Bar chart indicating the average number \(\pm\) SEM of Cy3-tagged N-terminal cMyBP-C fragments bound per micrometer micrometer of tightrope. \(n = \) number of tightropes imaged, above and within the bars are flowcell numbers. *Significant at \(P < 0.075\). Further examples of clustered binding are shown in SI Appendix, Fig. S2.

Inchingolo et al.

PNAS | April 2, 2019 | vol. 116 | no. 14 | 6831

BIOPHYSICS AND COMPUTATIONAL BIOLOGY
Filaments.

N-Terminal cMyBP-C Fragments Display Two Modes of Motion on Thin Filaments.

Dynamic imaging of cMyBP-C fragments on thin filament tightropes unexpectedly revealed that in addition to N-terminal fragments binding statically to thin filaments [Fig. 5A, horizontal trace (arrowhead)] a proportion of the fragments appeared to diffuse randomly along the thin filament [Fig. 5A, trace with γ-axis movement (star)]. Statically bound molecules were defined as not showing any apparent movement greater than one pixel in both dimensions (equivalent to 120 nm and 1 s) during the entire detection time window of >200 s [Fig. 5A, horizontal trace (arrowhead)]. This behavior was calcium-dependent for Cy3-C0C3 molecules; the proportion of kymograph traces showing diffusive Cy3-C0C3 motion decreased significantly ($P < 0.0075$) from 19.4 ± 4.6% (SEM, $n = 11$) at low calcium to 6.0 ± 1.8% (SEM, $n = 8$) at high calcium (Fig. 5B). By comparison, Cy3-C0C1f showed no significant difference ($P = 0.203$) in the proportion of diffusive molecules at both low and high calcium, 27.3 ± 2.2% (SEM, $n = 9$) and 32.3 ± 3.1% (SEM, $n = 6$), respectively. This was also the case for Cy3-C0C1 at low and high calcium, respectively ($P = 0.2542$). We also observed that some of the diffusing molecules would switch to static binding during their interaction with the thin filament (SI Appendix, Fig. S4), which was interpreted as being temporarily bound to a specific site in a partially exposed region of the thin filament; nonetheless, these molecules were classified as diffusive.

We calculated the diffusional characteristics summarized in SI Appendix, Table S1 using mean squared displacement (MSD):

$$MSD = \frac{1}{n} \sum_{t=1}^{n} (x(t) - x(0))^2 = 2D\tau^2,$$

where $D$ is the diffusion constant of the molecule, $\tau$ is the analysis time window, $x(t)$ is the position at time $t$, $x(0)$ is the starting reference position, and $\alpha$ is a coefficient that denotes the nature of the diffusion, where values close to 1 indicate random diffusion (36). Diffusion constants were transformed to log values before averaging and errors propagated to real numbers to provide the values in SI Appendix, Table S1.

Diffusion along a lattice can be described as multiple discrete steps with an average stepping rate. This definition allows us to calculate the average step size of the fragments on the thin filament, provided the stepping rate is known. We can calculate the stepping rate from attached lifetimes obtained from laser trap studies (37) that indicated C0C3, C0C1f, and C0C1 attach with two lifetime populations, <30 ms and >200 ms. Given that the longer events were ~60 times less frequently observed, and more likely to represent the a population of the stronger interactions that we report here (SI Appendix, Fig. S3), we used the short lifetime to calculate the step size for each fragment at low calcium, according to the equations below (38):

$$\text{stepping rate} = \frac{1}{\tau},$$

$$\text{step size} = l = \sqrt{2Dr^2},$$

where $r$ is the attached lifetime, $D$ is the diffusion constant, and $l$ is the average step size. This provides an average step size of 17 ± 3 nm (SD) for Cy3-C0C3, 12 ± 2 nm (SD) for Cy3-C0C1f, and 7 ± 1 nm (SD) for Cy3-C0C1. Due to the method of calculating these values it was not possible to generate a significance test; therefore, these values provide a range of step size from approximately one to three actin monomers.

Discussion

cMyBP-C plays a critical role in modulating cardiac contractility (39, 40), as evidenced by the high prevalence of cMyBP-C mutations in hypertrophic cardiomyopathy (41). One way for cMyBP-C to modulate cardiac contractility is to alter the sensitivity of the thin filament to calcium (10, 18, 27, 39), as reported here. To determine the underlying mechanism by which cMyBP-C enhances thin-filament activation at low calcium levels (18, 26), we directly visualized the impact of cMyBP-C-N-terminal fragments on the binding of individual myosin (S1-GFP) molecules along a single suspended actin-thin filament. Specifically, we observed that the COC3 N-terminal fragment enhanced myosin binding to thin filaments at low calcium (i.e., increased calcium sensitivity) and reduced myosin binding at high calcium. These results are consistent with our previous in vitro motility studies and that of others (18, 26), showing that cMyBP-C’s N terminus is sufficient to sensitize the thin filament to calcium and to modulate thin-filament sliding velocities at high calcium. The binding of
Cy3-C0C3 itself to the thin filament is seen to occur in clusters and this binding most likely displaces tropomyosin to a position that facilitates myosin binding (10, 18, 20). Surprisingly, ~20% of total Cy3-C0C3 binding events show diffusive behavior on the thin filament at low calcium, which may reflect the behavior of cMyBP-C’s N terminus within the sarcomere as it searches for its binding site on the thin filament.

**Specific cMyBP-C N-Terminal Domains Are Necessary for Thin-Filament Activation.** Activation of the thin filament at high calcium triggered significant S1-GFP binding, as expected (Fig. 2). Interestingly, the C0C3 N-terminal fragment sensitized the thin filament to calcium so that at low calcium, S1-GFP binding was equivalent to that for a fully calcium-activated thin filament (Fig. 2). The shorter N-terminal fragments (C0C1f and C0C1), with the C2 and C3 domains and a portion or the entire M-domain removed, were still capable of binding to thin filaments (Fig. 3). However, these fragments failed to sensitize the thin filament at low calcium (Fig. 2), measured as no change in S1-GFP binding in their presence. The failure of these shorter, murine cMyBP-C N-terminal fragments to sensitize the thin filament agrees with ATPase (19), in vitro motility (18, 26), and fragment-infused fiber data (11), suggesting that murine N-terminal fragments require at least C0-C2 to observe maximal thin filament calcium sensitization compared with the human N-terminal cMyBP-C fragments, where C0-C1 and C0-C1f are sufficient to sensitize the thin filament to calcium (19, 20, 42, 43). This species difference has been attributed to alternate sequences in the Pro-Ala linker between C0 and C1 as well as C1 itself (44).

The three-state model for thin-filament regulation (25) provides a useful mechanistic context for how C0C3 sensitizes the thin filament to calcium. Specifically, calcium binding to the thin filament permits tropomyosin movement on actin to expose myosin binding sites, shifting tropomyosin from the “blocked” to the “closed” position. As a result of myosin binding, tropomyosin is further displaced to the “open” or “myosin” position (24), therefore propagating the binding of additional myosins (29). By C0C3 binding to the thin filament at low calcium as it transiently enters the closed position, this N-terminal fragment may stabilize tropomyosin in the closed position, allowing myosin binding to actin, as supported by structural studies of tropomyosin movement caused by C0C2 binding to thin filaments (18). Since our data show a distinct difference between binding at low and high calcium concentrations, this may also suggest that additional binding sites become available once tropomyosin is displaced from the blocked position. The clustered or possible coordinated binding of C0C3 most likely represents binding to newly accessible actin adjacent to the location of a previously bound C0C3; however, intermolecular interactions between C0C3 molecules may also contribute.

**Modes of cMyBP-C N-Terminal Interactions with the Thin Filament.** The modular architecture of cMyBP-C provides the potential to structurally compartmentalize its functional capacities. Even though the very N-terminal domains, C0C1 and C0C1f, bind to actin (20, 21, 45, 46) as we have also shown previously (47), only C0C3 possesses the ability to sensitize the thin filament to low calcium while decreasing activation levels at high calcium. Unique to our study is the observation that upon binding of these N-terminal fragments to the thin filament, the fragments either remain stationary or undergo a diffusive-like movement along the thin filament. Specifically, for C0C3, how do these two distinct modes of interaction (i.e., 20% diffusing and 80% stationary) contribute to the thin-filament sensitization at low calcium? Multiple sites of N-terminal fragment interactions with the thin filament have been proposed based on actin cross-linking (48), fragment binding to actin in the laser trap (37), and electron microscopy studies (18, 20, 21, 46). At low calcium, tropomyosin on the thin filament should be in a dynamic equilibrium between the blocked and closed states (49). Presumably, the stationary Cy3-C0C3 molecules are stereospecifically bound to the thin filament through multiple binding sites, which could effectively shift tropomyosin’s equilibrium position to being predominantly closed and thus sensitize the thin filament to calcium. At low calcium the Cy3-C0C1 and Cy3-C0C1f have the same distribution of binding sites, and therefore the stationary fractions are not bound in the same manner as Cy3-C0C3, given the inability of these shorter fragments to sensitize the thin filament for myosin binding. As individual Ig-domains, both C0 and C1 can bind to the thin filament in several different configurations (20, 42), which is not the case for longer C0C2 and C0C3 fragments (21, 50). These structural studies support our proposal that the stationary Cy3-C0C3 molecules are the result of multiple sites of interaction with the thin filament, necessary to achieve calcium sensitization.

For the 20% of the Cy3-C0C3 fragments that diffuse at low calcium, we observed transient switching from diffusion to static binding on thin filaments (SI Appendix, Fig. S4). Such behavior would suggest that the diffusing molecules were interacting with regions of the thin filament more stably. However, for those transient static interactions that did not lead to extended binding this may suggest incomplete formation of a binding interface with the thin filament, which would otherwise result in activation and C0C3 recruitment. When diffusing, C0C3 molecules must weakly interact with the thin filament with a diffusional step size that we estimate to be between ~7 and ~17 nm, consistent with one to three actin monomers. This diffusive mode of motion may allow the N terminus of cMyBP-C to maintain contact with and scan the thin filament until such time that specific cMyBP-C binding sites are exposed on actin as tropomyosin undergoes its dynamic equilibrium between blocked and closed positions on the thin filament. Once statically bound to these sites, cMyBP-C may stabilize tropomyosin in the closed position (18, 25). This may also explain why at high calcium where the thin filament is predominantly in the closed state (25), Cy3-C0C3 binding to the thin filament is significantly increased (Fig. 3D) and almost entirely stationary (Fig. 5B) as cMyBP-C binding sites on actin would be readily exposed.
The clustering of C0C3 may compete with myosin for actin binding sites, as proposed in structural studies (18, 20, 21, 46) and cosedimentation competition studies (51), explaining the reduction in myosin binding observed on tightropes at high calcium (Fig. 2). Therefore, competitive inhibition of myosin binding by the N terminus of cMyBP-C may be one contributing factor to the reduced thin-filament velocity observed both in the C-zones of native thick filaments (32) and in the motility assay at high calcium (18, 26). However, reduced cross-bridge numbers in limited locations on the thin filament may not be enough to slow motility. It is possible that cMyBP-C binding to the thin filament may provide a load against which the remaining cross-bridges work, in turn slowing velocity (53, 54). Is in vivo clustering of cMyBP-C on the thin filament possible? cMyBP-C is positioned every ~43 nm along the thick filament within the C-zone. Since each thin filament in the muscle lattice is surrounded by three thick filaments, the individual cMyBP-C N termini from these thick filaments could cluster at a common point on the thin filament. In addition, HCM mutations of MyBP-C are known to lead to truncations (55), which could potentially compete with myosin as previously suggested (22). Fluorescence detection of Cy3-C0C3 binding and clustering at low vs. high calcium enabled us to fit the data by a chemical equilibrium model to estimate the affinity of these cMyBP-C fragments for thin filaments as 0.18 μM. This value is ~10-fold tighter than the ~2 μM reported for unregulated actin from ATPase inhibition studies (19) and up to 25-fold tighter than the affinities reported for mouse C0C2 using actin cosedimentation assays (48, 56). Some studies reporting the lower binding affinities (48) used bare actin, whereas thin filaments were used in the present study. Recent findings suggest that tropomyosin may bind cMyBP-C's N terminus (57); therefore, tropomyosin itself could act as a cofactor in the clustered binding of C0C3.

Conclusion
In this paper we addressed the nature of thin-filament activation/inhibition by the N terminus of cMyBP-C. Using a newly developed single-molecule imaging assay, we propose a mechanism by which cMyBP-C interacts with thin filaments using two different binding regimes in relaxing and activating calcium conditions. At low calcium (relaxing conditions), cMyBP-C senses the thin filament for changes in activation state due to positional fluctuations of tropomyosin. Sensing occurs by a weak binding mode in which the N terminus diffuses from actin monomer to monomer. Once specific cMyBP-C binding sites are encountered that allow subdomains C0 through C3 to bind more tightly, cMyBP-C can then effectively shift the tropomyosin equilibrium position from the blocked to the closed state, activating the thin filament. At high calcium (activating conditions), where calcium binding to tropomyosin itself shifts tropomyosin from the blocked to the closed position, cMyBP-C can bind tightly to the thin filament and compete for myosin binding. It is important to note that our studies define the cMyBP-C/C-terminal interactions with the thin filament but do not rule out potential interactions with the myosin head region as contributing to the thin filament sensitization. Regardless, our studies provide at least one molecular model for how cMyBP-C carries out its function within the confines of the sarcosome in vivo.

Materials and Methods
Protein Purification. Actin and myosin were purified from chicken pectoralis muscle (58), and recombiant human cardiac tropomyosin and tropo

Data Collection and Analysis. All experiments were performed in either high (100 μM, pCa 4) or low (0.1 μM, pCa 7) calcium buffers of 25 mM imidazole, pH 7.4, 4 mM MgCl2, 1 mM EGTA, and KCl adjusted to a final ionic strength of 51 mM using MaxChelator (63). Ten or more tightropes were imaged per condition (details of the experiments are provided in Results). Videos of S1-GFP binding to thin filaments were acquired at three frames per second (fps) for up to 1 min, while videos of Cy3-labeled cMyBP-C fragments were acquired at 1 fps for up to 5 min. To determine the spatial and temporal dynamics of S1-GFP or Cy3-labeled cMyBP-C fragments interacting with thin filaments, we transformed movies into kymographs where fluorophore position was plotted along the y axis and time on the x axis (Fig. 1D). Analysis of bound fluorescence position was performed using custom-written macros in ImageJ available online (klab.mechanicsandDynnodynamics.com). To measure the extent of S1-GFP binding we integrated the fluorescence intensity over the entire kymograph and normalized to the total number of pixels. All statistical P values mentioned were calculated using an unpaired t test, and P values <0.075 were considered significant. All SEM values were calculated using the number of flowcells, and in the case of comparative calculations SEM is a propagated error and therefore no n value is given. For data fitted using Microsoft Excel, the >95% CI values were calculated using the method of Kemmer and Keller (64).

ACKNOWLEDGMENTS. We thank Jeffrey Robbins and James Gulick (Cincinnati Children's Hospital Medical Center) for providing the expressed cMyBP-C N-terminal fragments and Greg Hoeprich, Lynn Chrin, and Christopher Berger (University of Vermont) for fluorescently labeling and characterizing the N-terminal cMyBP-C fragments. This work was supported by National Institutes of Health Grants HL126909 and AR067279 (to D.M.W. and H.L.) and LHR20401 (to M.J.P. and British Heart Foundation Grant F5/13/69/30504 (to N.M.K. and A.V.I.). This work was also supported in part by a generous gift to D.M.W. from Arnold and Mariel Goran.

1. Maron BJ, Maron MS (2013) Hypertrophic cardiomyopathy. Lancet 381:242–255.
2. Semsarian C, Ingles J, Maron MS, Maron BJ (2015) New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol 65:1249–1254.
3. Harvey PA, Leinwand LA (2011) The cell biology of disease: Cellular mechanisms of cardiomyopathy. J Cell Biol 194:355–365.
4. Yasuda M, Koshida S, Sato N, Obinata T (1995) Complete primary structure of chicken tropomyosin. Cell Cardiol 43:355.
5. Alyonycheva TN, Mikawa T, Reinach FC, Fischman DA (1997) Isoform-specific in-

Inchingolo et al.
8. Starr, R. Offer G. (1978) The interaction of C-protein with heavy meromyosin and subfragment-2. Biochem / 171:813-816.
9. Gruen M, Gautel M (1999) Mutations in beta-myosin S2 that cause familial hyper- tropic cardiomyopathy (FHO) abolish the interaction with the regulatory domain of myosin-binding protein-C. J Mol Biol 286:933-949.
10. Kompourakis T, Yan Z, Gautel M, Sun YB, Irving M (2014) Myosin binding protein-C activates thin filaments and inhibits thick filaments in heart muscle cells. Proc Natl Acad Sci USA 111:18763–18768.
11. Kunig G, et al. (2000) Myosin binding protein C, a phosphorylation-dependent force regulator in muscle that controls the attachment of myosin heads by its interaction with myosin S2. Circ Res 85:51–58.
12. Ratti J, Rostkova E, Gautel M, Pfuhl M (2011) Structure and interactions of myosin- binding protein C domain CO: Cardiac-specific regulation of myosin at its neck. J Biol Chem 286:12350–12358.
13. Nag S, et al. (2017) The myosin mesa and the basis of hypercontractility caused by hypertrophic cardiomyopathy mutations. Nat Struct Mol Biol 24:525–533.
14. Kessler RW, Craig R, Moss RL (2017) Phosphorylation of myosin binding protein C regulates myosin heads from the surface of cardiac thick filaments. Proc Natl Acad Sci USA 114:E1355–E1364.
15. McNamara JW, et al. (2017) MYBPC3 mutations are associated with a reduced super- relaxed state in patients with hypertrophic cardiomyopathy. PLoS One 12:e0180064.
16. McNamara JW, et al. (2016) Ablation of cardiac myosin binding protein-C disrupts the super-relaxed state of myosin in murine cardiomyocytes. J Mol Cell Cardiol 94:65–71.
17. Trivedi DV, Adhikari AS, Sarkar SS, Ruppel KM, Spudich JA (2018) Hypertrophic cardiomyopathy and the myosin mesa: Viewing an old disease in a new light. Biophys Rev 10:27–48.
18. Mun JY, et al. (2014) Myosin-binding protein C displaces tropomyosin to activate cardiac thin filaments and governs their speed by an independent mechanism. Proc Natl Acad Sci USA 111:2170–2175.
19. Bellknap B, Harris SP, White HD (2014) Modulation of thin filament activation of myosin ATP hydrolysis by non-terminal domains of cardiac myosin binding protein-C. Biochemistry 53:617–6724.
20. Harris SP, Bellknap B, Van Silver CE, White HD, Galvin VE (2016) CD and C1 N-terminal Ig domains of myosin binding protein C exert different effects on thin filament ac- tivity. Proc Natl Acad Sci USA 113:1538–1563.
21. Mun JY, et al. (2011) Electron microscopy and 3D reconstruction of F-actin decorated with cardiac myosin-binding protein C (MyBP-C). J Mol Biol 410:214–225.
22. Harris SP, et al. (2002) Hypertrophic cardiomyopathy in cardiac myosin binding protein-C knockout mouse. Circ Res 80:594–601.
23. Spudich JA, Huxley HE, Finch JT (1972) Regulation of skeletal muscle contraction. II. Structural studies of the interaction of the tropomyosin-tropomyosin complex with actin. J Mol Biol 72:619–632.
24. Pellecchia et al. (2006) A comparison of muscle thin filament models obtained from electron microscopy reconstructions and low-angle X-ray fibre diagrams from non- overlap muscle. J Struct Biol 155:273–284.
25. McKillop DF, Geeves MA (1999) Regulation of the interaction between actin and myosin subfragment-1: Evidence for three states of the thin filament. Biophys J 65: 693–701.
26. Razumova MV, et al. (2006) Effects of the N-terminal domains of myosin binding protein-C in an in vitro motility assay: Evidence for long-lived cross-bridges. J Biol Chem 281:35846–35854.
27. Razumova MV, Bezdol KL, Tu AY, Regnier M, Harris SP (2008) Contribution of the myosin binding protein C motif to functional effects in permeabilized rat trabeculae. J Gen Physiol 132:575–585.
28. Kessler RW, Shaffer JF, Harris SP (2011) Binding of the N-terminal fragment CO-C2 of cardiac MyBP-C to cardiac F-actin. J Struct Biol 174:44–51.
29. Desai R, Geeves MA, Kad NM (2015) Using fluorescent myosin to directly visualize cooperative activation of thin filaments. J Biol Chem 292:1915–1925.
30. Previs MJ, et al. (2013) Myosin-binding protein C corrects an intrinsic inhomogeneity in cardiac excitation-contraction coupling. Sci Adv 1:e1400025.
31. Iino R, Koyama I, Kusumi A (2001) Single molecule imaging of green fluorescent proteins in living cells: E-Cadherin forms oligomers on the free cell surface. Biophys J 80:2667–2677.
32. Loong CK, Zhou X, Chase PB (2012) Persistence length of human cardiac α-tropo- myosin measured by single molecule direct probe microscopy. PLoS One 7:e39676.
33. Bremel RD, Weber A (1972) Cooperation within actin filament in vertebrate skeletal muscle. Nat New Biol 236:97–101.
34. Kad MM, Kim S, Warshaw DM, VanBuren P, Baker JE (2005) Single-molecule crossbridge interactions with actin filaments regulated by tropo-in tropomyosin. Proc Natl Acad Sci USA 102:16990–16995.
35. Mayum R, Lehrer SS, Geeves MA (1999) Cooperativity and switching within the three- state model of muscle regulation. Biochemistry 38:1102–1110.